# Dosing and Tolerability of Deoxycholic Acid vs. Polidocanol in the Treatment of Neurofibromatosis Type 1 Cutaneous Neurofibromas

> **NCT06120036** · PHASE1 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 20 (actual)

## Conditions studied

- Neurofibromatosis 1

## Interventions

- **DRUG:** Kybella
- **DRUG:** Asclera

## Key facts

- **NCT ID:** NCT06120036
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-06
- **Primary completion:** 2025-01-09
- **Final completion:** 2025-01-09
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2025-02-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06120036

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06120036, "Dosing and Tolerability of Deoxycholic Acid vs. Polidocanol in the Treatment of Neurofibromatosis Type 1 Cutaneous Neurofibromas". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06120036. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*